IMNM Immunome Inc

Price (delayed)

$19.73

Market cap

$2.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.38

Enterprise value

$1.66B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 28

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are ...

Highlights
Immunome's quick ratio has surged by 106% YoY and by 46% QoQ
IMNM's EPS is up by 25% YoY and by 2.1% QoQ
The equity has soared by 92% YoY but it has contracted by 7% from the previous quarter
The revenue has shrunk by 63% YoY and by 42% QoQ
Immunome's gross profit has shrunk by 63% YoY and by 42% QoQ

Key stats

What are the main financial stats of IMNM

IMNM stock price

How has the Immunome stock price performed over time
Intraday
-0.4%
1 week
-12.47%
1 month
-15.43%
1 year
118.74%
YTD
-8.15%
QTD
-9.79%

Financial performance

How have Immunome's revenue and profit performed over time
Revenue
$4.02M
Gross profit
$4.02M
Operating income
-$238.81M
Net income
-$224.59M
Gross margin
100%
Net margin
-5,593.8%
IMNM's net margin has dropped by 198% year-on-year and by 83% since the previous quarter
Immunome's operating margin has plunged by 198% YoY and by 84% from the previous quarter
The revenue has shrunk by 63% YoY and by 42% QoQ
Immunome's gross profit has shrunk by 63% YoY and by 42% QoQ

Price vs fundamentals

How does IMNM's price correlate with its fundamentals

Growth

What is Immunome's growth rate over time

Valuation

What is Immunome stock price valuation
P/E
N/A
P/B
3.79
P/S
555.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
412.26
IMNM's EPS is up by 25% YoY and by 2.1% QoQ
The equity has soared by 92% YoY but it has contracted by 7% from the previous quarter
The price to book (P/B) is 11% lower than the 5-year quarterly average of 4.3 but 9% higher than the last 4 quarters average of 3.5
IMNM's price to sales (P/S) is 111% higher than its last 4 quarters average of 264.3
The revenue has shrunk by 63% YoY and by 42% QoQ

Efficiency

How efficient is Immunome business performance
IMNM's ROS has shrunk by 198% YoY and by 83% QoQ
The ROIC has plunged by 115% YoY and by 42% from the previous quarter
Immunome's ROE has increased by 40% YoY and by 11% from the previous quarter
The company's return on assets rose by 34% YoY and by 10% QoQ

Dividends

What is IMNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMNM.

Financial health

How did Immunome financials performed over time
The current ratio has soared by 107% YoY and by 48% QoQ
Immunome's quick ratio has surged by 106% YoY and by 46% QoQ
IMNM's debt is 99% smaller than its equity
The equity has soared by 92% YoY but it has contracted by 7% from the previous quarter
Immunome's debt to equity has plunged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.